Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, AstraZeneca announed. These results were presented at the San Antonio Breast Cancer Symposium 2024 and “build on the positive primary results published in The New England Journal of Medicine,” the company added. At a median follow-up of 6.1 years in eligible patients, who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, results showed Lynparza reduced the risk of death by 28% versus placebo. In addition, 87.5% of patients treated with LYNPARZA remained alive versus 83.2% of those on placebo.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo announce BTD for datopotamab deruxtecan
- AstraZeneca reports ‘positive’ results from AMPLIFY Phase 3 trial
- AstraZeneca granted priority review for Imfinzi sBLA
- AstraZeneca sBLA for Imfinzi granted Priority Review in MIBC
- AstraZeneca announces FDA approval for Imfinzi
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
